PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.36%
Cash & equivalents yoy growth below half of CRVO's 57.15%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
2.36%
Below half of CRVO's 607.97%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.66%
Other current assets growth < half of CRVO's 15.96%. David Dodd sees a leaner approach to short-term items.
1.99%
Below half of CRVO's 513.23%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.06%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.24%
Below half of CRVO's 1996.77%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Below half of CRVO's 565.10%. Michael Burry sees a potential red flag for stagnation or capital shortage.
22.15%
Above 1.5x CRVO's 6.78%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of CRVO's 144.81%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
20.63%
Similar yoy to CRVO's 20.77%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.37%
Less than half of CRVO's -100.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
3.44%
Less than half of CRVO's 20.77%. David Dodd sees far fewer liability expansions relative to competitor.
6.90%
Less than half of CRVO's 33.76%. David Dodd sees fewer share issuances vs. competitor.
-3.28%
0.75-0.9x CRVO's -4.07%. Bill Ackman questions if competitor reinvests profits more robustly.
100.00%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-0.05%
Below half CRVO's 836.53%. Michael Burry sees potential underperformance in building shareholder capital.
1.71%
Below half CRVO's 565.10%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.63%
Higher Total Investments Growth compared to CRVO's zero value, indicating better performance.
-6.71%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
-2.57%
Less than half of CRVO's -57.15%. David Dodd sees better deleveraging or stronger cash buildup than competitor.